New Drug Approved by FDA to Treat Opioid Dependence

zubsolvOrexo pharmaceuticals recently announced that it gained approval from the U.S. Food and Drug Administration (FDA) for its new drug Zubsolv to treat opiod abuse and addiction.

According to a statement from the company’s President and CEO Nikolaj Sørensen, “Orexo has developed Zubsolv as a novel sublingual therapy meeting the needs of millions of patients that suffers from opioid dependence to offer them a new choice of treatment. Zubsolv has in previous studies showed a high acceptability compared to the leading treatment modalities in the market.”

The latest National Survey on Drug Use and Health (NSDUH) stated that roughly 2.2 million people aged 12 or older in the U.S. deal with abuse or dependence on opiates such as heroin or prescription painkillers, though Orexo estimates that number to be more than twice as many. There has also been the recent news from the CDC stating that the number of overdose deaths from opioid pharmaceuticals has increased exponentially in the past decade.

Many people addicted to opiates have cited the agonizing withdrawal symptoms as being deterrents for trying to stop using them. This, along with cost and bed availability continue to be major blocks for this subgroup of drug abusers.

Hopefully having more treatment options available for people struggling with opioid abuse or addiction will encourage them to seek help. If you have a loved one in need of drug or alcohol rehabilitation, contact Family First Intervention to learn more about our treatment referral and intervention services.

Mike Loverde

As a Certified Intervention Professional (CIP), member of NAATP, NAADAC, and accredited by the Pennsylvania Certification Board, Mike Loverde knows first-hand what it’s like to live life with addiction. By overcoming it, he had a calling to work with others who struggle with drug and alcohol addictions—the people who use and the families who feel helpless watching them decay.

With thousands of interventions across the United States done and many more to come, Loverde continues to own the intervention space, since 2005, by working with medical doctors, psychiatrists, psychologists and others who need expert assistance for their patients who need intervention. To further his impact on behavioral health and maximize intervention effectiveness, Loverde is near completion of a Masters in Addiction Studies (MHS) accreditation, as well as a Licensed Independent Substance Abuse Counselor (LISAC), and is committed to attaining the designation of a Licensed Professional Counselor (LPC).

More Posts - Website

Follow Me:
TwitterFacebookLinkedIn